Medical device company inHeart has began enrollment in Europe for a randomized control trial for the company's artificial intelligence (AI)-enabled digital twin of the heart.
The inEurHeart clinical study is a multicenter, prospective, blind randomized controlled trial that aims to compare the efficiency and efficacy of image-guided ventricular tachycardia ablations to conventional, catheter-based methods. The company said it wants to enroll 112 patients in 15 heart centers across four European countries over the next 12 months.
The inHeart software uses a proprietary segmentation algorithm that analyzes CT or MR images to create interactive 3D heart models. The company said this could help physicians develop treatment strategies for individual patients.
